Zomedica (ZOM) said Tuesday it struck a deal to market Cresilon's Vetigel hemostatic gel product line on an exclusive basis in the US and on a non-exclusive basis in other regions.
Under the license and supply agreement, Zomedica said it will assume responsibility for supplying US customers and will collaborate with Cresilon to support customers outside the country.
Vetigel is a plant-based formula to stop bleeding when applied to the source, the veterinary healthcare company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments